2017). Oral hypoglycemic agents are categorized based on their mechanism of action: those that primarily stimulate insulin secretion, including sulfonylureas, glinides, and dipeptidyl peptidase-IV inhibitors (DPP-4i), and those that work through other mechanisms, including biguanides, thiazolidinediones (TZDs), α-glycosidase inhibitors, and sodium-glucose cotransporter-2 inhibitors (SGLT2i). Although pharmacological treatments are effective and cost-effective, prolonged use can lead to side effects and complications such as hypoglycemia, fluid retention, and edema (Diamant and Heine 2003). The gene discussed is SLC5A2; the disease is Hypoglycemia.